Filana Therapeutics
FLNA
66 hedge funds and large institutions have $48.4M invested in Filana Therapeutics in 2014 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 23 reducing their positions, and 20 closing their positions.
10% less funds holding
Funds holding: 73 → 66 (-7)
26% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 23
30% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 20
53% less capital invested
Capital invested by funds: $104M → $48.4M (-$55.1M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.3M |
| 2 |
First Eagle Investment Management
New York
|
+$1.57M |
| 3 |
MERSOM
Municipal Employees' Retirement System of Michigan
Lansing,
Michigan
|
+$797K |
| 4 |
Millennium Management
New York
|
+$433K |
| 5 |
D.E. Shaw & Co
New York
|
+$377K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSP
Madison Street Partners
Denver,
Colorado
|
-$7.34M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$7.11M |
| 3 |
GCM
Gruss Capital Management
New York
|
-$2.44M |
| 4 |
SC
Sophrosyne Capital
New York
|
-$2.27M |
| 5 |
JIR
James Investment Research
Alpha,
Ohio
|
-$651K |
FLNA Hedge Fund Activity: Q4 2014 in Review
66 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q4 2014, worth a combined $48.4M — down 53% from $104M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of FLNA and 14 opened new positions — a net loss of 6 holders — while 23 trimmed existing stakes and 17 added.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $4.3M. The largest seller was Madison Street Partners, exiting entirely with an estimated $7.34M sold.
- 66 institutional investors held Filana Therapeutics (FLNA) as of Q4 2014, down from 73 in Q3 2014.
- Funds reported $48.4M of Filana Therapeutics stock for Q4 2014, down 53% quarter-over-quarter.
- 14 funds opened new Filana Therapeutics positions in Q4 2014 and 20 closed out, a net change of -6 holders.
- The largest Filana Therapeutics buyer in Q4 2014 was Nantahala Capital Management, an estimated $4.3M added.
- The largest Filana Therapeutics seller in Q4 2014 was Madison Street Partners, an estimated $7.34M sold.
Based on aggregated 13F filings for Q4 2014.